Dominance of mutations in epigenetic regulators and a diversity of signaling alterations in blast‐phase <scp><i>BCR::ABL1</i></scp>‐negative myeloproliferative neoplasms
Authors: Petruta Gurban, Cristina Mambet, Anca Botezatu, Laura G. Necula, Lilia Matei, Ana Iulia Neagu, Ioana Pitica, Marius Ataman, Aurelia Tatic, Alexandru Bardas, Mihnea A. Gaman, Camelia Dobrea, Mihaela Dragomir, Cecilia Ghimici, Silvana Angelescu, Doina Barbu, Oana Stanca, Marina Danila, Nicoleta Berbec, Andrei Colita, Ana Maria Vladareanu, Saviana Nedeianu, Mihaela Chivu‐Economescu, Coralia Bleotu, Daniel Coriu, Elise Sepulchre, Gabriela Anton, Carmen C. Diaconu, Stefan N. Constantinescu
Journal: American Journal of Hematology (2024)

BCR::ABL1-negative myeloproliferative neoplasms (MPNs) can evolve to secondary acute myeloid leukemia (sAML) or blast-phase (BP) MPN, a very severe condition with lack of effective therapy.1 Leukemic transformation (LT) of MPNs displays a variable incidence according to MPN phenotype: 9%–13% in primary myelofibrosis (PMF), 3%–7% in polycythemia vera (PV), and 1%–4% in essential thrombocythemia (ET).1 Here, we investigated the mutational landscape, copy number variations (CNVs), and uniparental disomy (UPD) events in BP-MPN cases that were diagnosed over a 6-year period of monitoring in three different hematology units (Fundeni Clinical Institute, Coltea Hospital and Emergency University Hospitals, Bucharest, Romania) and the patterns of clonal evolution in a subset of patients with available paired chronic phase (CP)-BP DNA samples. The study was approved by the local ethics committee (No. 136/06.02.2017 rev. no.131/18.01.2019) and was performed in conformity with the Declaration of Helsinki. A written informed consent was provided by each patient at collection of samples that were referred to Stefan S Nicolau Institute of Virology, Romania, for molecular analysis. Clinical, morphological, and immunophenotypic data were provided from the medical records for all recruited patients. Peripheral blood or bone marrow (BM) mononuclear cells were isolated and processed to obtain various cell fractions. CD3+ T cells were used as reference for germline mutations. Molecular testing for MPN-driver mutations, targeted next-generation sequencing (NGS), whole-exome sequencing (WES), single nucleotide polymorphism (SNP) microarray analysis, and multiplex ligation-dependent probe amplification (MLPA) were performed as described by manufacturers (see Supplemental file; Data S1 for a complete description of methods). A total of 33 patients (median age, 63 years; 57.6% males) were diagnosed with BP-MPN between 2017 and 2023, in the above-mentioned centers, including 20 post-PMF (60.4%), and 13 post-ET/PV (39.4%) cases (Table S1). A prior stage of secondary myelofibrosis was confirmed by BM biopsy in 8 out of 13 post-ET/PV AML (61.5%) patients. According to morphologic and immunophenotypic data, sAML cases were classified as AML with myelodysplasia-related changes (n = 4, 12.1%) and AML, not otherwise specified (n = 29, 87.9%), as follows: AML with minimal differentiation (n = 6, 18.2%), AML without maturation (n = 12, 36.4%), acute myelomonocytic leukemia (n = 6, 18.2%), acute monocytic leukemia (n = 1, 3%), pure erythroid leukemia (n = 1, 3%), and acute megakaryoblastic leukemia (n = 3, 9.1%). Concerning the MPN drivers detected at CP, 60.6% of patients carried JAK2 V617F mutation, 21.2% harbored calreticulin (CALR) mutations (5 type1/type 1-like, 2 type2/type-2 like), and 18.2% were classified as triple-negative (TN-MPNs). We report a median age at BP diagnosis significantly lower in CALR-mutated and TN-MPNs compared with JAK2-mutated ones (54, 56, vs. 67.5 years, p = .014), and a median time from MPN diagnosis to BP conversion significantly shorter in TN-MPNs compared with CALR and JAK2-mutated ones (1, 3 vs. 7 years, p = .0476) (Table S1). Overall, the median survival was 3 months (range, 1–54 months) without significant differences between the three groups of patients (Table S1). By targeted NGS/WES testing of matched blast and CD3+ DNA samples, a total number of 62 somatic mutations apart from MPN-driver mutations were detected. The most frequent anomalies were represented by epigenetic mutations (72.8%), followed by TP53 mutations (33.3%), mutations of signaling molecules (24.2%, significantly more frequent in JAK2 V617F-negative groups, p = .005), transcriptional regulators (21.2%), and mRNA splicing factors (15.2%) (Table S1). The frequencies of individual mutations are shown in Figure 1A. Prevalence of prior exposure to ruxolitinib versus hydroxyurea was similar among the ASXL1, EZH2, and/or NRAS-mutated patients (Figure 1B). Importantly, a high occurrence of multiple CNVs (≥3) (42.4%) was detected by SNP array and MLPA. Del(17p) including TP53 gene was the most frequent anomaly, followed by del(5q), del(7q) including EZH2 gene, del(20q), gain of chromosome 21, and other less frequent anomalies. Also, UPD events involving JAK2 (9p), TP53 (17p), CBL (11q), and NRAS (1p) were observed in the analyzed cohort (Figure 1C). TP53 mutations co-occurred with multiple CNVs in 10 cases (30.3%) and with del(17p) in 9 cases (27.3%), being absent in CALR-mutated patients. All 5 detected RUNX1 mutations were identified as comutations to JAK2 V617F. The co-occurrence of JAK2-TP53 was found in 6 patients at BP (18.2%) (Figure 1D). Detailed information about demographics, genomic aberrations, therapy in CP and BP, clinical outcome, and survival for each BP-MPN case is displayed in Table S2. Thirteen paired CP-BP DNA samples were available for combined genomic analysis. In CP-MPN patients, the median number of aberrations was 3 (maximum 8). Eleven patients carried MPN-driver mutations: seven JAK2 V617F, three CALR type1/type 1-like, and one with both CALR type 2 and low-burden JAK2 V617F. All of them had at least one additional genetic lesion, the most frequent being TP53 heterozygous mutations, del(5q), and ASXL1 mutations. In BP-MPN, the median number of aberrations increased to 6 (maximum 9). JAK2 V617F was lost in three BP-MPNs, while CALR mutations were present at both MPN and LT in all cases. Loss of heterozygosity (LOH) events affecting TP53, NF1 and SUZ12 (17q), and CBL, as well as RUNX1 mutations, EZH2 mutations, del(7q), and 21q gain were detected exclusively in BP (Figure 1E). Based on the VAFs of the somatic mutations identified by targeted NGS/WES and also on the information provided by SNP array/MLPA in paired CP-BP DNA samples, four patterns of clonal evolution were inferred of which three involved the MPN phenotypic driver mutation clone(s), while one involved the non-MPN-mutated clone (Figure 1F): (i) a linear pattern, in which the leukemic clone developed from the driver mutation clone through acquisition of one or more genomic alterations; (ii) acquisition of a MPN-driver mutation in HSC carrying a pre-existing mutation that was also present in the leukemic clone; (iii) a branched subclonal evolution in which several subclones derived from the driver mutation clone coexisted and one of them, by acquiring novel genomic aberrations, gained growth advantage and promoted leukemogenesis; and (iv) acquisition of genomic aberrations leading to proliferation advantage and transformation in a non-MPN clone in patients where two independent clones or subclones existed at CP, one of them carrying the MPN-driver mutation. Additionally, a linear pattern was observed in TN-MPNs that progressed to BP, in which the leukemic clone developed from a TP53 clone or subclone present at CP that predominantly gained del(17p) among multiple CNVs. While these patterns have been described before, the precise acquired mutations in the patterns are of interest and show a diversity of pathways leading to LT. For example, signaling mutations in NRAS, CBL, NF1, and PTPN11 occurred at BP. It is also interesting that competition between mutated JAK2 and CALR clones has been detected, with one leading to LT, as well as competition between different TP53-mutated clones. Individual profiles of CP-BP genomic aberrations in 12 patients are described in Figure S1. Clonal evolution of patient 13# was not presented as it was previously published.2 Our results point to a dominance of epigenetic mutations in BP-MPN patients (72.8% of cases). When considering also CNVs that affect chromatin modifiers and DNA methylation, 84.8% of patients exhibited epigenetics alterations. Particularly, anomalies of EZH2 gene were relatively frequent in JAK2 V617F-mutated and TN-MPN patients. In serial DNA samples, EZH2 anomalies were detected exclusively in BP. In agreement, in a single-cell analysis of clonal evolution in paired CP-BP samples,3 EZH2 was recurrently mutated or affected by CNVs in transition to BP. In BP-MPN patients carrying TP53 alterations, epigenetic modifications were observed in 75% of cases. In paired-sample analysis, the same TP53 mutations found in BP were already present in CP-MPNs in a heterozygous state, as previously reported.4 Chronic inflammation was recently demonstrated to play an important role in clonal evolution of TP53-mutant MPNs by suppressing unmutated HSCs, and therefore conferring a fitness advantage to TP53-positive HSCs and progenitors.5 As expected, in our BP-MPN patients, multi-hit TP53 were dominant, mostly represented by a single TP53 missense mutations accompanied by del(17p) (Supplemental file, Figure S2). Among TP53 missense mutations, structural mutants were more frequent than contact ones (Table S3). Gain of chromosome 21 was observed in one type-2 CALR and two JAK2 V617F-positive patients (trisomy 21 in one patient and a duplication of 21q11.2-q22.3 in two cases, both associated with multiple CNVs and one with TP53 mutations). This is in agreement with a recent study6 that identified an amplified region of chromosome 21 as a recurrent event in BP-MPN patients, being accompanied by chromothripsis and displaying a very aggressive phenotype.6 This genetic alteration leads to an upregulation of DYRK1A gene (21q.22) that in functional studies promoted genomic instability and increased JAK/STAT signaling.6 Compared with JAK2-mutated MPNs that exhibited complex patterns of clonal evolution, giving rise to either JAK2-mutated AML or JAK2 wild-type AML, CALR-mutated PMF patients evolved to BP by acquiring novel genomic alterations on the top of MPN-driver mutation. Paired-sample analysis in two PMF patients carrying type 1 CALR mutation that developed sAML with hyperleukocytosis resembling BP chronic myeloid leukemia detected the presence of LOH events leading to a hyperactive RAS/tyrosine kinase receptor signaling, respectively. At time of LT, one patient displayed NF1 biallelic inactivation, while another carried a homozygous CBL mutation due to an UPD11q. Regarding mutated CALR proteins and granulocytosis, it has been shown that besides activating thrombopoietin receptor, which explains the ET and PMF phenotypes, these mutated proteins can also activate granulocyte colony-stimulating factor receptor (GCSFR).7 Further studies are required to assess if extreme granulocytosis was related to activation of GCSFR or to other cytokines associated with inflammation in PMF, for example, granulocyte-macrophage colony-stimulating factor. The profile of genomic aberrations in AML post-TN-PMF was characterized by a high-incidence of biallelic TP53 alterations (66.6%) and multiple CNVs (66.6%). The spectrum of anomalies together with a shorter median time from diagnosis to BP revealed common features with fibrotic myelodysplastic neoplasms (f-MDS). The distinction between TN-PMF and f-MDS is often challenging, both entities being associated with a higher risk of LT at 3 years from diagnosis.8 As a limitation of our study, inherently related to the small number of patients included in the study, we could not assess the impact on survival of the detected genomic alterations in a multivariable analysis. To conclude, we highlight the overwhelming prominence of epigenetic alterations and importance of serial evaluation of clonal evolution in MPNs for early prediction of disease transformation. We also describe a diversity of signaling mutations contributing to transformation. Petruta Gurban involved in conceptualization, data curation, formal analysis, investigation, methodology, and writing/review and editing. Cristina Mambet involved in conceptualization, data curation, formal analysis, investigation, methodology, and writing/review and editing. Anca Botezatu involved in data curation, formal analysis, investigation, methodology, and writing/review and editing. Laura G. Necula involved in formal analysis, investigation, methodology, and writing/review and editing. Lilia Matei involved in formal analysis, investigation, methodology, and writing/review and editing. Ana Iulia Neagu involved in data curation, investigation, methodology, and writing/review and editing. Ioana Pitica involved in formal analysis, investigation, methodology, and writing/review and editing. Marius Ataman involved in investigation, methodology, and writing/review and editing. Aurelia Tatic involved in investigation, methodology, and writing/review and editing. Alexandru Bardas involved in investigation, methodology, and writing/review and editing. Mihnea A. Gaman involved in investigation, methodology, and writing/review and editing. Camelia Dobrea involved in investigation, methodology, and writing/review and editing. Mihaela Dragomir involved in investigation, methodology, and writing/review and editing. Cecilia Ghimici involved in investigation, methodology, and writing/review and editing. Silvana Angelescu involved in investigation, methodology, and writing/review and editing. Doina Barbu involved in investigation, methodology, and writing/review and editing. Oana Stanca involved in investigation, methodology, and writing/review and editing. Marina Danila involved in investigation, methodology, and writing/review and editing. Nicoleta Berbec involved in investigation, methodology, and writing/review and editing. Andrei Colita involved in investigation, methodology, and writing/review and editing. Ana Maria Vladareanu involved in investigation, methodology, and writing/review and editing. Saviana Nedeianu involved in data curation, formal analysis, investigation, methodology, and writing/review and editing. Mihaela Chivu-Economescu involved in data curation, formal analysis, investigation, methodology, and writing/review and editing. Coralia Bleotu involved in data curation, formal analysis, investigation, methodology, and writing/review and editing. Daniel Coriu involved in formal analysis, investigation, and writing/review and editing. Elise Sepulchre involved in data curation, formal analysis, investigation, methodology, and writing/review and editing. Gabriela Anton involved in conceptualization, validation, and writing/review and editing. Carmen Cristina Diaconu, senior author, involved in conceptualization, funding acquisition, methodology, project administration, resources, supervision, validation, and writing/review and editing. Stefan N. Constantinescu, senior author, involved in conceptualization, funding acquisition, methodology, resources, supervision, validation, and writing/review and editing. This research was supported by grant funded by Competitiveness Operational Programme (COP) A1.1.4. ID: P_37_798 MYELOAL-EDIAPROT, Contract 149/26.10.2016, (MySMIS2014+: 106774), MyeloAL Project. Funding to SNC is acknowledged from Ludwig Institute for Cancer Research, Fondation contre le cancer F/2022/2048, Salus Sanguinis, and Fondation "Les avions de Sébastien," Projet de recherche FNRS n°T.0043.21 and WelBio F 44/8/5 – MCF/UIG – 10 955. PG is employed by Cytogenomic Medical Laboratory, Bucharest, Romania. SNC is cofounder of MyeloPro Diagnostics and Research GmbH, Vienna, Austria. The other authors have no financial or nonfinancial interests to disclose. Data are available at the Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, Bucharest, and are accessible from the corresponding author upon reasonable request. Data S1. Supplemental Text 1. methodology. Table S1. Clinical data, hematological parameters, and profile of genomic aberrations of BP-MPN patients stratified by driver mutations. Table S2. Information about demographics, genomic aberrations, therapy at CP and BP, clinical outcome, and survival for each BP-MPN case. Table S3. Characterization of TP53 missense mutations. Figure S1. Patterns of clonal evolution in MPN patients. Figure S2. Spectrum of TP53 alterations. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.